Perphenazine has been on the market since 1957. For most of its early decades it was one of the most widely used antipsychotics in the world. Then second-generation drugs arrived, and perphenazine — like most first-generation agents — was widely displaced by aripiprazole, olanzapine, risperidone, and their kin. In 2005, the landmark CATIE trial compared perphenazine head-to-head with several newer agents and found it broadly comparable in real-world effectiveness. That result rewrote a chapter of psychiatry. Two decades on, perphenazine is no longer a default first-line drug, but it has earned its quiet place in the modern toolkit.
Perphenazine is a mid-potency first-generation antipsychotic that performed comparably to several second-generation agents in the CATIE trial and remains an inexpensive, evidence-supported option for schizophrenia.
The drug itself
Perphenazine is a piperazine phenothiazine — chemically related to chlorpromazine but with much higher potency and a different side effect profile. It blocks dopamine D2 receptors, with modest serotonin, histamine, alpha-adrenergic, and anticholinergic activity. Its receptor profile sits in the middle of the first-generation potency spectrum — less sedating and less anticholinergic than chlorpromazine, but with a higher EPS risk; more sedating and more metabolically forgiving than haloperidol or fluphenazine.
What CATIE actually showed
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) was a NIMH-funded study published in the New England Journal of Medicine in 2005 (Lieberman et al.). It enrolled nearly 1,500 patients with chronic schizophrenia and compared perphenazine with olanzapine, quetiapine, risperidone, and ziprasidone. The primary outcome was time to discontinuation for any reason — a real-world measure that captured both efficacy and tolerability.
Key results:
- Olanzapine had the longest time to discontinuation overall — but also the most weight gain and metabolic problems
- Perphenazine was not statistically different from quetiapine, risperidone, or ziprasidone on time to discontinuation
- EPS rates with perphenazine were not dramatically higher than with second-generation comparators
- Perphenazine was substantially less expensive than the second-generation drugs
The conclusion that shifted practice: "newer" did not automatically mean "better tolerated" or "more effective." For many patients, an older drug like perphenazine was a perfectly reasonable starting point — particularly when cost was a barrier.
FDA-approved indications
- Schizophrenia in adults
- Severe nausea and vomiting in adults (rarely used today for this)
Dosing
Typical dosing for schizophrenia is 8 to 16 mg twice or three times daily, with maximum doses around 64 mg/day. Older or sensitive patients are started at lower doses. Most patients reach a therapeutic range within 2 to 4 weeks of titration.
Side effect profile
Movement effects
Perphenazine causes EPS, akathisia, and tardive dyskinesia at rates higher than most second-generation drugs but lower than haloperidol or fluphenazine. CATIE found EPS rates of about 8% per year, similar to several second-generation comparators. See EPS overview and TD article.
Sedation
Moderate, between low-potency phenothiazines and high-potency typicals. Often manageable.
Weight gain and metabolic effects
Generally modest. CATIE found less weight gain and lower rates of new diabetes than with olanzapine, comparable to risperidone in metabolic profile. This is one of perphenazine's significant advantages.
Anticholinergic effects
Mild to moderate — dry mouth, constipation, blurred vision, urinary hesitancy.
Hyperprolactinemia
Common, with the usual menstrual, breast, and sexual side effects. See hyperprolactinemia article.
Cardiovascular effects
Mild QTc prolongation; less than thioridazine or droperidol. Orthostatic hypotension uncommon at typical doses.
Less common but serious effects
- Neuroleptic malignant syndrome — rare, life-threatening
- Photosensitivity and skin reactions — phenothiazine class effect
- Hepatic effects — uncommon liver enzyme elevations
- Lowered seizure threshold — modest
- Blood dyscrasias — rare
You develop high fever, severe muscle stiffness, confusion, or rapid heartbeat — these can signal NMS. Also seek care for new sustained involuntary movements of the face, tongue, or limbs.
Drug interactions
Perphenazine is metabolised by CYP2D6 and other enzymes. Strong CYP2D6 inhibitors can raise levels meaningfully. Combining with other QT-prolonging or CNS-depressant drugs requires caution.
Where perphenazine fits today
Perphenazine is rarely a first-line choice in 2026 — most algorithms still start with second-generation agents. But it has clear roles:
- Patients responding well to it historically — switching off something that works is rarely justified
- Cost-constrained situations — generic perphenazine is among the least expensive antipsychotics
- Patients with significant metabolic concerns — alternative to weight-heavy second-generation drugs
- International settings — perphenazine remains widely available globally where some newer drugs are not
Who tends to do well on perphenazine
- People who responded to it before
- People concerned about weight gain on second-generation drugs
- People who need an inexpensive option
- People who don't tolerate the sedation of low-potency typicals
Who might choose differently
- People with prior bad EPS
- Older adults at higher TD risk
- People with significant cardiac arrhythmia history
- People particularly sensitive to prolactin elevation
Practical questions to ask your prescriber
- Why perphenazine specifically rather than a newer agent?
- What dose are we targeting?
- Will we monitor for movement side effects on a schedule (such as the AIMS exam)?
- What should I do if I notice tremor, stiffness, or restlessness?
The big picture
Perphenazine is neither a relic nor a cure-all. It is a serious, effective, inexpensive antipsychotic with a balanced first-generation profile. CATIE reminded the psychiatric field that decades of clinical experience and reasonable side effects can outweigh the marketing advantages of newer drugs. For the right patient — especially one who has done well on it before, or for whom metabolic side effects of second-generation agents have been intolerable, or for whom cost is a real barrier — perphenazine remains a meaningful choice. Whether it fits your situation is best decided in conversation with a prescriber who knows your history and your goals.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication.